To unlock the power of data for advanced medical insights.

Company & History

apoplex medical technologies GmbH

apoplex medical technologies has been at the forefront of stroke prevention for over 20 years, specializing in the development of applications to support atrial fibrillation detection. The core element of our stroke risk analysis solutions SRA®, SRA®+, and the upcoming SRA® Pro is the fully automated detection of indications of atrial fibrillation as well as the identification of patients with an increased probability of paroxysmal atrial fibrillation in flicker-free episodes.

More than 20 peer-reviewed studies have shown that our SRA® system not only improves patient care but also streamlines clinical workflows and optimizes operational efficiency. Trusted by 40% of stroke units in Germany, SRA® has become a cornerstone in reshaping patient pathways and supporting healthcare professionals in preventing strokes.

We work closely with healthcare professionals to develop disruptive technologies rooted in clinical evidence. By advancing stroke prevention, we aim to save lives and significantly reduce the number of strokes caused by undetected atrial fibrillation.

Our History

2004
apoplex medical technologies GmbH was founded. The topic of stroke continues to be the focus of our company – but with reference to one of the most important risk factors: Atrial fibrillation. We intensively studied the clinical picture of paroxysmal atrial fibrillation to recognize and clarify it at an early stage. The special feature of this type of atrial fibrillation is that it only occurs episodically and then disappears again. This factor makes it more difficult to detect. We set out to change that!
The result of our efforts is the patented SRA® (Stroke Risk Analysis), offered as a service to doctors in private practice and clinics.
2007
Using data from university hospitals, we started to develop robust algorithms to further optimize our stroke “early warning system”.
In 2007, we won the Innovation Award of the KKH – which then decided to cooperate with us as the first nationwide health insurance company. The integrated health care (IHC) based on SRA® was to become the longest running IHC contract ever.
2012
Our long research and development phase finally paid off. Many renowned professional publications reported on the excellent results from studies with SRA® conducted at national and international institutions. In 2012, a study was published in the renowned Stroke Journal in cooperation with the University of Heidelberg. The result: SRA® is significantly superior to standard examinations.
2018
This year, we entered into a co-promotion partnership with the global biopharmaceutical company Bristol Myers Squibb. Our aim was to further embed the SRA® technology into routine care.
‍After successfully establishing ourselves on the German market, expansion into other European countries commenced in 2018. What started with the German-speaking region soon extended to Spain and England in the same year. In Spain, a successful multicentre study in Catalonia led to our service qualifying for reimbursement by health insurance and further satisfied customers. Expansion of our sphere of activity to Italy followed just one year later.
Since 2022
We continue to do everything we can to improve stroke prevention with further innovations – while avoiding the drastic consequences of incidents for those affected. Artificial intelligence (AI) opens completely new possibilities for us to achieve what we set out to do and to plan it even better and faster.
‍We want to continue to grow and expand our leadership role as a powerful, forward-looking and reliable partner for stroke-related diagnostic support applications.

Key Facts

Employees
0
Countries
0
Clinics
0
Studies
0
Patents
0

Our Medical Advisory Board

Dr. Ignacio H. Medrano

Neurologist. Founder at Savana & at Mendelian Savana Singularity University
LEARN MORE

Dr. Ignacio H. Medrano

Neurologist. Founder at Savana & at Mendelian Savana Singularity University

Dr. Ignacio H. Medrano is a Consultant Neurologist with training in Healthcare Management and experience in Clinical research strategies (formerly responsible for +500 researchers). A Singularity University graduate, he is a founder at Mendelian in the UK (AI for diagnose of rare diseases) and at Savana (Clinical Research using AI on Electronic Medical Records).

In 2021 Forbes praised Dr Ignacio H. Medrano, including him in the list of the 100 most creative Spaniards in the business world; in 2023 he was included in the list of the 23 changemakers. From the European Commision to the British Royal Academy of Science, Ignacio is a well-known international speaker.

Dr. Thomas Johannes Neuberger

Senior Physician Internal Medicine & Cardiology Medical Manager at Apoplex
LEARN MORE

Dr. Thomas Johannes Neuberger

Senior Physician Internal Medicine & Cardiology Medical Manager at Apoplex

Dr. Thomas Johannes Neuberger is a Specialist in Internal Medicine and Cardiology with extensive clinical experience in cardiovascular care. Since 2011 he has served as Senior Physician in Internal Medicine and Cardiology at Pirmasens Hospital, and since 2014 he has also worked as Medical Manager at Apoplex Medical Technologies GmbH, focusing on innovative cardiovascular diagnostics.

He studied Medicine at Goethe University Frankfurt and earned his doctorate with research on Heart Rate Turbulence as an autonomic marker for arrhythmia risk stratification, contributing to advances in cardiac risk assessment.

Our Certificates

GDPR Compliant

Your path to “Stroke Unit” certification
OPEN

ISO 13485

OPEN

ISO 27001

OPEN
Scroll to Top